We are live on ! Find out more
NXTC icon

NextCure
NXTC

43 hedge funds and large institutions have $19.6M invested in NextCure in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $18.4M → $19.6M (+$1.22M)

0.06% more ownership

Funds ownership: 3.92% → 3.98% (+0.06%)

2% less funds holding

Funds holding: 44 → 43 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
12
Closed
7
Calls
$231K
Puts
–
Net Calls
+$231K
Net Calls Change
+$75K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$642K
2
BCM
BML Capital Management
Indiana
+$492K
3
Millennium Management
Millennium Management
New York
+$188K
4
Morgan Stanley
Morgan Stanley
New York
+$141K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$93K

Top Sellers

Rank Fund Capital Flow
1
CPA
Cardiff Park Advisors
California
-$369K
2
Goldman Sachs
Goldman Sachs
New York
-$347K
3
Renaissance Technologies
Renaissance Technologies
New York
-$260K
4
BlackRock
BlackRock
New York
-$196K
5
BCM
Bridgeway Capital Management
Texas
-$80.2K

NXTC Hedge Fund Activity: Q1 2023 in Review

43 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2023, worth a combined $19.6M — up 6.6% from $18.4M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NXTC and 6 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 6 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $642K. The largest seller was Cardiff Park Advisors, exiting entirely with an estimated $369K sold.

  • 43 institutional investors held NextCure (NXTC) as of Q1 2023, down from 44 in Q4 2022.
  • Funds reported $19.6M of NextCure stock for Q1 2023, up 6.6% quarter-over-quarter.
  • 6 funds opened new NextCure positions in Q1 2023 and 7 closed out, a net change of -1 holder.
  • The largest NextCure buyer in Q1 2023 was Tang Capital Management, an estimated $642K added.
  • The largest NextCure seller in Q1 2023 was Cardiff Park Advisors, an estimated $369K sold.

Based on aggregated 13F filings for Q1 2023.